GSK1349572 CAS 1051375-16-6

Khoom Piav Qhia:

Khoom Lub Npe: GSK1349572 CAS TSIS TAU: 1051375-16-6

Lub ntsiab lus:

(4R, 12aS) -N- (2,4-difluorobenzyl) -7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido [1 [ GG] #39 ;, 2': 4,5] pyrazino [2,1-b] [1,3] oxazine-9-carboxamide;

S/GSK1349572;

2H-Pyrido [1', 2': 4,5] pyrazino [2,1-b] [1,3] oxazine-9-carboxamide, N-[(2,4] -difluorophenyl) methyl] -3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-, (4R, 12aS)-;

Tshuaj& Lub Cev Muaj Zog:

Tshwm sim: Dawb rau daj daj daj

Kev Ntsuas: ≥99.0%

Ceev: 1.53

Melting Point: 188-192 ℃

Kub Point: 669.0 ± 55.0 ℃ (Kwv yees)

Flash Point: 358.4 ± 31.5 ℃

Vapor Siab: 0.0 ± 2.1 mmHg ntawm 25 ℃

Index ntawm Refraction: 1.650

Dolutegravir (DTG) yog tshuaj pom zoo los ntawm FDA rau kev kho kab mob HIV. Dolutegravir yog ib qho inhibitor integrase. Paub tias S/GSK1349572 lossis tsuas yog" 572" cov tshuaj raug muag raws li Tivicay los ntawm GlaxoSmithKline (GSK). Thaum Lub Ob Hlis, 2013 Lub Chaw Saib Xyuas Khoom Noj thiab Tshuaj tau tshaj tawm tias nws yuav taug qab sai sai dolutegravir' txoj kev pom zoo. Thaum Lub Yim Hli 13, 2013, dolutegravir tau pom zoo los ntawm FDA. Lub Kaum Ib Hlis 4, 2013, dolutegravir tau pom zoo los ntawm Health Canada. Thaum Lub Ib Hlis 16, 2014, Tivicay tau pom zoo los ntawm European Commission rau kev siv thoob plaws European Union.

Yog tias koj txaus siab rau peb cov khoom lossis muaj lus nug, thov koj xav tiv tauj peb!

Cov khoom lag luam nyob rau hauv patent tau muab rau R& D lub hom phiaj nkaus xwb. Txawm li cas los xij, lub luag haujlwm zaum kawg tshwj xeeb tshaj yog nrog tus neeg yuav khoom.

Cim npe nrov: gsk1349572 cas 1051375-16-6, tuam ntxhab, cov chaw muag khoom, lub Hoobkas, yuav, hauv Tshuag

• Tug: Metoclopramide Hydrochloride CAS 54143-57-6
• Tom ntej: 4-Aminosalicylic Acid CAS 65-49-6